News and Events

Clinical study follows men with specific genetic changes to determine their risk for developing prostate cancer

Prostate cancer (PC) is the most common malignancy in American men. There is increasing evidence that there may be a link between PC and men who have a family history of ovarian or breast cancer. As researchers have learned more about the role of genetics in PC, they have taken a new approach to screening for the disease—targeting men whose genetic profiles put them at risk for developing PC.

Clinical trial to determine whether antibiotics can boost immune response in treating liver cancer

A new clinical trial at the NCI’s Center for Cancer Research is set to explore if eliminating certain bacteria in the gut will boost the immune system response in patients who have hepatocellular carcinoma and liver metastases.

Julius Strauss discusses promising immunotherapy drug for patients with HPV-related cancers

Julius Strauss, M.D., Assistant Research Physician in the Laboratory of Tumor Immunology and Biology, discussed a promising immunotherapy drug for patients with HPV-related cancers in a recent NCI Cancer Currents blog post. According to results from a phase 1 clinical trial, 33 percent of the 36 patients on the trial with HPV-positive tumors responded to the drug, and four of the responses lasted longer than 18 months. “This drug is a promising agent for patients with HPV-related cancers and may potentially benefit these patients more than traditional checkpoint therapies,” said Dr. Strauss.

Brid Ryan cohosts NCI Minority Health Month Facebook Live

The National Cancer Institute hosted a Facebook Live entitled, “A Dialogue on Cancer Disparities, Prevention, and Research.”The event featured Brid M. Ryan, Ph.D., M.P.H., Investigator in the Laboratory of Human Carcinogenesis, as well as Worta McCaskill-Stevens, M.D., M.S., from the Division of Cancer Prevention, and Christina Dieli-Conwright, Ph.D., M.P.H., from the University of Southern California. They discussed cancer disparities and the work being done to help reduce them.

A patient’s 10-year journey to moxetumomab for hairy cell leukemia

Randy, a father, husband, engineering quality consultant and lifelong “Motor City” resident, was diagnosed with hairy cell leukemia in 1998 at the age of 41. After participation in a clinical trial at the NIH Clinical Center, his body has shown a complete response to the drug moxetumomab pasudotox, which was developed at the National Cancer Institute’s Center for Cancer Research.

Photomicrograph showing graft-versus-host disease in the skin

Cyclophosphamide works in an unexpected way to curb graft-vs-host disease in mice

For years it has been assumed that cyclophosphamide helps reduce the severity of graft-versus-host disease by eliminating alloreactive T cells, but new evidence reveals a different reason.

Marston Linehan receives 2019 Urology Care Foundation Distinguished Mentor award

Marston Linehan, M.D., Chief of the Urologic Oncology Branch, has received the 2019 Urology Care Foundation Distinguished Mentor award. The award recognizes Dr. Linehan’s outstanding track record of fostering the next generation of urologic researchers by providing excellent training and guidance to early-career investigators.

iCURE helps a first-generation American reach her goal

Anaisa Quintanilla-Arteaga’s ultimate goal is to be the Latina scientist she wishes she had seen when she was younger, and “hopefully help younger generations of Latinas realize that they belong and can thrive in STEM, too.” An iCURE fellowship is helping her achieve that dream.

Majority of patients with advanced multiple myeloma respond to CAR T-cell therapy targeting an anti-B-cell maturation antigen in a phase I trial

A phase I clinical trial of 33 patients infused with a CAR T-cell therapy using T cells genetically engineered to express an anti-B-cell maturation antigen (BCMA) CAR showed that 85 percent of patients had the burden of their advanced multiple myeloma cut by half or more.

Heritable mutations may indicate responsiveness to platinum chemotherapy in malignant mesothelioma

In a genetic analysis of 434 patients with malignant mesothelioma who had undergone platinum chemotherapy, those who carried heritable mutations in BAP1and other DNA repair genes had significantly longer overall survival than those without these mutations. The findings hint at personalized approaches to the disease.

Breadcrumb